Objectives: Early osteoporotic fractures have a great impact on the disease progression, the first fracture being a major risk factor for further fractures. Subsequently, the efficacy of antiosteoporotic treatments in the younger women appears of utmost interest. Strontium ranelate is an anti-osteoporotic treatment, simultaneously reducing bone resorption while promoting bone formation. Its efficacy against vertebral fractures is presently assessed in a subset of women aged 50 to 65 years.
Methods: SOTI was an international, double-blind, placebo-controlled trial, supporting the efficacy of strontium ranelate 2g/day orally in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. 353 of these randomized women, aged 50 to 65 years were included in this analysis over 4 years.
Results: Over 4 years, strontium ranelate significantly reduced the risk of vertebral fracture by 35% (RR=0.65; 95%CI [0.42;0.99], p<0.05). In the strontium ranelate group, the BMD mean change from baseline increased by 15.8% at lumbar spine and 7.1% at femoral neck.
Conclusion: These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women with severe osteoporosis aged 50 to 65 years and confirms the efficacy of this anti-osteoporotic treatment to prevent vertebral fractures, whatever the age of the patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.